Shots:
- The US FDA has granted Breakthrough Device Designation to a wearable Vancomycin therapeutic drug monitoring (TDM) Patch, designed to continuously monitor vancomycin levels & support faster, more personalized dosing decisions
- In Feb 2026, Nutromics published first-in-human data on its molecular monitoring platform in Nature Biotechnology, plus the company has conducted ICU clinical studies in Australia, with further US studies in preparation
- Nutromics is targeting a potential US launch in 2027, subject to regulatory authorization, while developing additional sensors for sepsis & cardiovascular disease
Ref: Nutromics| Image: Nutromics | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
